The Glutaminase (GLS) enzyme plays a critical role in glutaminolysis, which is an important energy source for proliferating cells. It is upregulated by c-Myc, an oncogenic transcription factor, and has been identified as a target for the treatment of cMyc-expressing cancers. GLS is also thought to play a pathogenic role on HAD using a human HIV-1 infected macrophage system, where it causes an increase in excitotoxic glutamate. The project aims to identify small molecule inhibitors of GLS through qHTS and explore their potential therapeutic application in cancer and inflammatory neurological disorders, such as HAD and multiple sclerosis. Is the molecule effective to this assay?